Vuzix (VUZI) investor relations material

Opening remarks and agenda

• Management highlighted forward-looking statements and risks, referencing recent SEC filings and the focus on OEM products and waveguides as primary growth engines.

• Emphasis on transition from smart glasses pioneer to OEM products and advanced optical manufacturing, highlighting execution, manufacturing scale, and customer-funded growth as core themes.

Financial performance review

• Q1 2026 revenues were $1.4 million, down 12% year-over-year, mainly due to lower M400 sales.

• Engineering services revenue rose 36% to $0.35 million.

• Gross loss increased to $0.4 million, attributed to lower sales and fixed manufacturing costs.

• R&D expenses rose 16% to $3 million, driven by headcount and equipment investments.

• Net loss narrowed to $7.1 million ($0.09/share) from $8.6 million ($0.11/share) in Q1 2025.

• Cash and cash equivalents of $20.2M as of 3/31/26, with no debt and $5.8 million raised via ATM facility.

• Annual cash operating expense reduced by ~25% since 2024, reflecting disciplined capital allocation.

Strategic initiatives and plans

• Focus remains on OEM and waveguide businesses, with new product shipments to Amazon and a leading auto manufacturer.

• Expansion into OEM and defense sectors, leveraging waveguide technology for scalable optics and secure U.S. manufacturing.

• Strategic partnerships with Quanta and multiple display ecosystem players to support various display technologies.

• Manufacturing capacity and R&D infrastructure expanded in Rochester, NY, including new chemistry lab, advanced tooling, increased automation, and quality control.

• Enterprise smart glasses serve as a validation engine for higher-scale OEM and waveguide opportunities.

• OEM programs move from development to production, with customer-funded engineering creating capital-efficient paths.

• Defense sector momentum includes six- and seven-figure development orders and expanded U.S. manufacturing.

• Waveguide technology positioned as the strategic core, enabling scalable, prescription-ready AR/AI smart glasses.

• Over 500 patents and patents pending worldwide, reinforcing long-term industry positioning.